ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 8.5% in January

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 2,150,000 shares, a decrease of 8.5% from the December 31st total of 2,350,000 shares. Based on an average trading volume of 252,300 shares, the days-to-cover ratio is presently 8.5 days.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 28th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Finally, Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Trading Down 0.5 %

NASDAQ ANIP traded down $0.31 during trading hours on Monday, reaching $58.33. The company’s stock had a trading volume of 22,135 shares, compared to its average volume of 165,350. The firm has a fifty day simple moving average of $56.61 and a 200-day simple moving average of $58.53. The stock has a market cap of $1.23 billion, a P/E ratio of -106.05 and a beta of 0.74. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business earned $1.05 EPS. Equities analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,381 shares of company stock valued at $2,441,556. 12.70% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Sei Investments Co. increased its position in ANI Pharmaceuticals by 27.8% during the 2nd quarter. Sei Investments Co. now owns 14,473 shares of the specialty pharmaceutical company’s stock valued at $922,000 after purchasing an additional 3,152 shares during the period. Marshall Wace LLP acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $253,000. AQR Capital Management LLC grew its position in shares of ANI Pharmaceuticals by 44.8% during the 2nd quarter. AQR Capital Management LLC now owns 17,527 shares of the specialty pharmaceutical company’s stock worth $1,116,000 after buying an additional 5,419 shares during the period. Millennium Management LLC grew its position in shares of ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after buying an additional 209,272 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in shares of ANI Pharmaceuticals by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock worth $605,000 after buying an additional 1,211 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.